Endeavor BioMedicines Raises $132.5M in Funding to Accelerate Clinical Development and Manufacturing of Candidate Medicines.

Endeavor BioMedicines' Series C Financing

Key Highlights:

• Series C Financing: Closed a $132.5 million Series C financing round, including the conversion of a $5 million convertible instrument.
• Lead Candidate: ENV-101, an inhibitor of the Hedgehog (Hh) signaling pathway, in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
• Second Candidate: ENV-501, a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

Endeavor BioMedicines' Target Market

• Target Market: Patients with life-threatening diseases, specifically those with idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and HER3-positive solid tumors.
• Healthcare Providers and Specialists: Pulmonologists, oncologists, and other healthcare professionals specializing in treating patients with the target diseases.
• Pharmaceutical Companies and Research Institutions: Potential partners for further clinical development and research collaborations.

What Endeavor BioMedicines Needs to Buy

• Clinical Research and Development Services: Collaborations with contract research organizations (CROs) and research institutions for advancing clinical development of their lead and second candidates.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers for the production of their medicines and managing a reliable supply chain.
• Regulatory and Compliance Expertise: Engaging with regulatory consultants and experts to navigate the complex regulatory landscape in the biotechnology and pharmaceutical industries.